Developmental Funds

发展基金：项目摘要 西特曼癌症中心(SCC)的西特曼投资计划(SIP)包括一系列筹资机制 通过竞争性的资助机会支持创新科学研究；投资于我们的 社区、集水区和教员；以及战略招聘努力，以加强和多样化SCC的科学 研究公文包。SCC目前的五年战略规划以及SCC集水区的需求提供了 这是所有资金决定的基础。SCC高级领导层(SL)设计的SIP与其 中心的总体愿景，最优先考虑的是促进跨学科、翻译和 合作研究。 从癌症中心支持赠款(CCSG)发展基金部分获得的资金是 SCC慈善资产大幅增加，每年向SCC提供约400万美元(400万美元) 会员通过SIP研究发展奖(RDA)每两年资助一次。SCC SL设计 Sip RDA将包括一个模仿NIH审查过程的严格同行审查过程。SCC SL和SCC 管理部门密切监控计划成果的进度和生产率，包括初级员工的参与 调查人员。自2015年以来，24名R01之前的获奖者(42%)是初级调查人员，他们总共获得了450万美元 在SIPRDA资金方面。在这24家公司中，11家(46%)总共至少利用了一项外部奖励 总导演票房1350万美元。SIPRDA计划还包括为没有资助的申请者提供指导机会， 包括初级教员在内，在结束时与SIPRDA主席会面，讨论批评和改进 审核周期。重新提交的成功率为37%，这表明这些会议对 在未来的资助周期中重新申请的未资助的SIP RDA申请者。 2013-2017年间，SCC通过改善计划向所有七家SCC的调查人员发放了总计2360万美元的赔偿金 研究项目。到目前为止，SCC教职员工已经利用了1.2亿美元的外部直接成本(总成本为1.73亿美元) 资金问题。这1.2亿美元包括44个NCI奖项(8350万美元，占总杠杆的70%)和31个NIH和其他癌症 同行评审的赠款(2850万美元，占杠杆总额的23%)；因此，从学校改善计划筹集的所有资金中有93%来自 来自同行评议的奖项。在下一个项目期，SCC将增加对SIP的承诺和投资 通过支持新的和合作的研究，显著推进癌症发现，经常性的年度 投资招聘教员，并为没有资金和/或资金不足的研究人员提供资金- 启动了临床试验。CCSG发展基金的资金将继续发放给SCC成员 通过SIPRDA计划。

DEVELOPMENTAL FUNDS: PROJECT SUMMARY Siteman Cancer Center’s (SCC’s) Siteman Investment Program (SIP) includes a portfolio of funding mechanisms that support innovative scientific research through competitive funding opportunities; investments in our community, catchment, and faculty; and strategic recruitment efforts to strengthen and diversify SCC’s scientific research portfolio. SCC’s current five-year strategic plan, as well as the needs of SCC’s catchment area, provide the foundation for all funding decisions. SCC Senior Leadership (SL) designed the SIP to align closely with their overall vision for the center, with the highest priority placed on promotion of transdisciplinary, translational, and collaborative research. Funding received from the Cancer Center Support Grant (CCSG) Developmental Funds component is significantly augmented by SCC philanthropic assets to provide approximately $4 million ($4M) per year to SCC members through the SIP Research Development Award (RDA) biannual funding opportunity. SCC SL designed SIP RDA to include a rigorous peer-review process modeled after the NIH review process. SCC SL and SCC Administration closely monitor program outcomes for progress and productivity, including participation by junior investigators. Since 2015, 24 Pre-R01 awardees (42%) were junior investigators who collectively received $4.5M in SIP RDA funding. Of those 24, 11 (46%) have already leveraged at least one external award, collectively totaling $13.5M in directs. The SIP RDA program also includes a mentoring opportunity for unfunded applicants, including junior faculty, to meet with the SIP RDA chair to discuss critiques and improvements at the end of the review cycle. The success rate for resubmissions is 37%, which suggests that these meetings are valuable for unfunded SIP RDA applicants who reapply in future funding cycles. From 2013–2017, SCC awarded a total of $23.6M through the SIP to investigators across all seven of SCC’s research programs. To date, SCC faculty have leveraged $120M in direct costs ($173M total costs) in external funding. This $120M includes 44 NCI awards ($83.5M, 70% of total leveraged) and 31 NIH and other cancer peer-reviewed grants ($28.5M, 23% of total leveraged); thus, 93% of all dollars leveraged from the SIP come from peer-reviewed awards. In the next project period, SCC will grow its commitment to and investment in SIP to significantly advance cancer discovery through support of novel and collaborative research, recurring annual investment for faculty recruitment, and by providing funding for unfunded and/or underfunded investigator- initiated clinical trials. Funding from CCSG Developmental Funds will continue to be awarded to SCC members through the SIP RDA program.